By API User
AdAlta Limited (ASX:1AD) (“AdAlta” or “the Company”), developer of next generation cell and protein therapeutic products is presenting at the 3rd ANZ Biologics Festival being held in Melbourne, Australia from 4-5 February, 2025. The 3rd ANZ Biologics Festival 2025 is the region’s premier conference that aims to gather the innovators, pioneers, and leaders in the … Continued
By API User
Highlights • Optiscan initiates pre-clinical GI study with University Medical Center Mainz, Germany • To support the study, Optiscan has completed its first prototype to collect images from the GI tract • The study will assess Optiscan’s Gen2 real-time imaging capability on GI tract tissue • Data from the study will be used to determine the utility of … Continued
By API User
Optiscan Imaging Limited (ASX:OIL) (‘Optiscan’ or the ‘Company’), a leader in medical imaging using confocal laser endomicroscopy, is pleased to announce its Appendix 4C Quarterly Cashflow report and business update for the quarter ended 31 December 2024 (the ‘Quarter’). All financial results are in Australian dollars and are unaudited. Highlights for the Quarter • Product … Continued
By API User
Board renewal and recently assembled clinical advisory team enhance leadership capabilities as “East-to-West” strategy and AD-214 are progressed. Key highlights • Expanded advisor network engaged to support “East to West” cellular therapy strategy• First non-binding term sheet executed for “East to West” cellular therapy strategy • AD-214 partnering to be supported by new advisors, stronger execution capabilities … Continued
By API User
OncoSil Medical Ltd (ASX: OSL), a medical device company focused on localised treatments for patients with unresectable locally advanced pancreatic cancer (LAPC), is pleased to announce its Appendix 4C cash flow report for the quarter ended 31 December 2024 (Q2 FY25), along with the following financial and operational update. Key Highlights • OncoSil signs distribution agreements … Continued
By API User
Pancreatic cancer treatment device company OncoSil Medical Limited (ASX:OSL) (“OncoSil” or “the Company”) is pleased to announce that it has received Medical Device Regulation (MDR) certification from BSI, the EU Notified Body. The certification includes the lifting of existing post-market restrictions. This milestone highlights the growing robust clinical evidence supporting the safety of the OncoSil™ device and … Continued
By API User
22 January 2025 – Sydney, Australia | ASX-listed LTR Pharma Limited (ASX:LTP) has announced a strategic partnership with Symbion Pty Ltd, which is one of the largest pharmaceutical wholesalers in Australia. This will facilitate the nationwide distribution of novel nasal spray treatment for Erectile Dysfunction (ED), SPONTAN®. The non-exclusive agreement, which commences on 1 March … Continued
By API User
Pancreatic cancer treatment device company OncoSil Medical Limited (ASX:OSL) has announced the appointment of Ms. Lel Smits as a NonExecutive Director to the Board of OncoSil Medical, effective immediately. Ms. Smits brings a wealth of expertise in governance, strategy, risk oversight, and corporate communications, with a distinguished career advising over 500 ASX-listed management teams and Boards. … Continued
By API User
Pancreatic cancer treatment device company OncoSil Medical Limited (ASX:OSL) has announced the appointment of Ms. Lel Smits as a NonExecutive Director to the Board of OncoSil Medical, effective immediately. Ms. Smits brings a wealth of expertise in governance, strategy, risk oversight, and corporate communications, with a distinguished career advising over 500 ASX-listed management teams and Boards. … Continued
By API User
X4 to receive a €28.5 million upfront payment and up to €226 million in potential regulatory and commercial milestone payments in addition to tiered, double-digit royalties up to the mid-twenties Upfront non-dilutive funds strengthen X4’s balance sheet as enrollment ramps up in the company’s global Phase 3 clinical trial in chronic neutropenia Agreement underscores Norgine’s … Continued
